MedTrace Logo

Skin Inflammation and PK of Azithromycin

NCT06170983 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-12-14

No results posted yet for this study

Summary

This study will investigate the tissue distribution of azithromycin in healthy, artificially inflamed and actually infected tissue of humans.

Conditions

  • Skin Infection

Interventions

DRUG

Azithromycin

500 mg once daily for 3 days

DIAGNOSTIC_TEST

Biopsy

Skin punch biopsy

OTHER

Skin inflammation model

LPS- or imiquimod induced skin inflammation

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-01-01
Completion
2026-07-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06170983 on ClinicalTrials.gov